Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4006895 · 1 trial · 2 indications
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4006895 of Part A (SAD) | EXPERIMENTAL | Single-ascending doses of LY4006895 administered intravenously (IV) |
| Placebo Part A | PLACEBO_COMPARATOR | Placebo administered IV |
| LY4006895 of Part B (MAD) | EXPERIMENTAL | Multiple-ascending doses of LY4006895 will be administered IV |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo administered IV |
| Name | Type | Description |
|---|---|---|
| LY4006895 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria for Part A and Part B: \- Have a body mass index (BMI) within the range 18 to 40 kilogram per square meter (kg/m²) For Part A: * Are overtly healthy as determined by medical evaluation. Rescreening is not allowed in this study For Part B: * Have early symptomatic AD, as defin...
Top 20 of 24 competitors
LY4006895 is an investigational small molecule being developed for Alzheimer's disease. It is currently in Phase 1 clinical development, studied in healthy participants and those with early symptomatic Alzheimer's disease. The drug is being developed by Eli Lilly and Company.
LY4006895 is a small molecule, but its specific molecular target has not been disclosed. It is being studied for its potential effect in Alzheimer's disease, a neurological condition. The mechanism of action is not publicly detailed at this time.
LY4006895 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker LLY. The company is conducting a Phase 1 clinical trial of the drug in the United States and Japan.
LY4006895 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 1 study is currently recruiting participants to evaluate the drug in healthy individuals and those with early symptomatic Alzheimer's disease.
LY4006895 is being studied in one Phase 1 clinical trial, identified as NCT06657768. This randomized, double-blind, placebo-controlled study is recruiting 128 participants in the United States and Japan. The trial includes healthy volunteers and individuals with early symptomatic Alzheimer's disease.
LY4006895 is a unique investigational drug candidate developed by Eli Lilly and Company. No alternative names for this compound have been disclosed. It is being studied specifically for Alzheimer's disease and is not known to be identical to any other marketed medication.